Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Given radiation therapy in different ways may kill more tumor cells.
This randomized phase II trial studies radiation therapy to see how well it works in treating patients with prostate cancer.
This study is for male subjects with prostate cancer. The purpose of this study is to find out what effects, good and/or bad, there are to adding the new investigational drug, IMC-A12, to standard hormone therapy which is used to treat prostate cancer. Subjects will go through a screening period before they can begin receiving treatment on this study. If the subject is eligible to participate, subjects will be "randomized" into one of the study groups. If they are in Group 1 (often called "Arm 1") they will receive standard hormone therapy plus IMC-A12. Leuprolide acetate (Lupron) or goserelin acetate (Zoladex) will be given as a shot in the muscle once either every 4, 12, 16, 24 or 52 weeks at the discretion of the physician. If they are in Group 2 (often called "Arm 2") they will receive standard treatment with hormone therapies. Leuprolide acetate (Lupron) or goserelin acetate (Zoladex) will be given as a shot in the muscle once either every 4, 12, 16, 24 or 52 weeks at the discretion of the physician. The study treatment is expected to last about seven cycles (28 weeks). The study doctor will ask the subject to visit the office for follow-up exams every six months for the first two years and then once a year for a maximum of five years from the time the subject began the study.
Men who have received radiation treatment for prostate cancer within the last 5 years are needed. One blood draw is required. The Investigator will then check the blood samples for specific markers. These markers will then be compared to possible side effects that have been experienced from radiation treatment. Individuals react to medical treatment differently. The goal of the study is to be able to determine the dose of radiation treatment that is best suited for each man by checking these markers before he begins his treatment.
Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone aganist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen deprivation therapy is more effective for prostate cancer.
This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer. Patients will be randomly assigned to one of three study groups: radiation therapy to the prostate bed only; hormone therapy plus radiation to the prostate bed; and hormone therapy plus radiation to the prostate bed and to the pelvic lymph nodes.